Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023; 73(1):17-48. [DOI:10.3322/caac.21763] [PMID]

Liu H, Dong Z. Cancer etiology and prevention principle: "1 + X". Cancer Research. 2021; 81(21):5377-95. [DOI:10.1158/0008-5472.CAN-21-1862] [PMID]

Blackadar CB. Historical review of the causes of cancer. World Journal of Clinical Oncology. 2016; 7(1):54-86. [DOI:10.5306/wjco.v7.i1.54] [PMID]

Nisar S, Hashem S, Macha MA, Yadav SK, Muralitharan S, Therachiyil L, et al. Exploring dysregulated signaling pathways in cancer. Current Pharmaceutical Design. 2020; 26(4):429-45. [DOI:10.2174/1381612826666200115095937] [PMID]

Ong JY, Torres JZ. Dissecting the mechanisms of cell division. The Journal of Biological Chemistry. 2019; 294(30):11382-90. [DOI:10.1074/jbc.AW119.008149] [PMID]

de Oliveira SA, Borges R, Dos Santos Rosa D, de Souza ACS, Seabra AB, Baino F, et al. Strategies for cancer treatment based on photonic nanomedicine. Materials (Basel). 2021; 14(6):1435. [DOI:10.3390/ma14061435] [PMID]

Shekar N, Mallya P, Gowda DV, Jain V. Triple-negative breast cancer: Challenges and treatment options. International Journal of Research in Pharmaceutical Sciences. 2020; 11(2):1977-86. [Link]

Javani Jouni F, Abdollahi V, Zadehmodarres S, Abbasinia H, Asnaashari M, Zafari J. Combination of cisplatin treatment and photodynamic therapy attenuates cisplatin-induced cell toxicity in A2780 and A2780-CP cervical cancer cell lines. Lasers in Medical Science. 2022; 37(2):1175-80. [DOI:10.1007/s10103-021-03369-z] [PMID]

Brown A, Kumar S, Tchounwou PB. Cisplatin-based chemotherapy of human cancers. Journal of Cancer Science & Therapy. 2019; 11(4):97. [PMID]

Aldossary SA. Review on pharmacology of cisplatin: Clinical use, toxicity and mechanism of resistance of cisplatin. Biomedical and Pharmacology Journal. 2019; 12(1):7-15. [DOI:10.13005/bpj/1608]

Ho GY, Woodward N, Coward JIG. Cisplatin versus carboplatin: Comparative review of therapeutic management in solid malignancies. Critical Reviews in Oncology/Hematology. 2016; 102:37-46. [DOI:10.1016/j.critrevonc.2016.03.014] [PMID]

Zafari J, Javani Jouni F, Jamali S, Marzoghi S, Zadehmodarres S, Razzaghi M. The effect of cisplatin-low-level laser therapy on cell viability and death of LNCaP prostate cancer cell line. Lasers in Medical Science. 2022; 37(2):1283-8. [DOI:10.1007/s10103-021-03386-y] [PMID]

Jouni FJ, Zafari J, Abbasifard M, Jafarisani M, Sadeghi H, Bagheri-Hosseinabadi Z. Erratum to: Synergistic effects on taurine and cisplatin on lung cancer cells (A549). Cytology and Genetics. 2023; 57(4):384-5. [DOI:10.3103/S0095452723040047]

Jafarzadeh E, Montazeri V, Aliebrahimi S, Sezavar AH, Ghahremani MH, Ostad SN. Combined regimens of cisplatin and metformin in cancer therapy: A systematic review and meta-analysis. Life Sciences. 2022; 304:120680. [DOI:10.1016/j.lfs.2022.120680] [PMID]

Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: Molecular mechanisms of action. European Journal of Pharmacology. 2014; 740:364-78. [DOI:10.1016/j.ejphar.2014.07.025] [PMID]

Makovec T. Cisplatin and beyond: Molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiology and Oncology. 2019; 53(2):148-58. [DOI:10.2478/raon-2019-0018] [PMID]

Rivel T, Ramseyer C, Yesylevskyy SO. Permeation of cisplatin through the membranes of normal and cancer cells: A molecular dynamics study. bioRxiv. 2018; 375980:1-29. [DOI:10.1101/375980]

Tchounwou PB, Dasari S, Noubissi FK, Ray P, Kumar S. Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy. Journal of Experimental Pharmacology. 2021; 13:303-28. [DOI:10.2147/JEP.S267383] [PMID]

Jiang M, Wang CY, Huang S, Yang T, Dong Z. Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway. American Journal of Physiology. 2009; 296(5):F983-93. [DOI:10.1152/ajprenal.90579.2008] [PMID]

Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorganic Chemistry. 2019; 88:102925. [DOI:10.1016/j.bioorg.2019.102925] [PMID]

Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: A review for chemists. Dalton Transactions (Cambridge, England: 2003). 2018; 47(19):6645-53. [DOI:10.1039/C8DT00838H] [PMID]

Manohar S, Leung N. Cisplatin nephrotoxicity: A review of the literature. Journal of Nephrology. 2018; 31(1):15-25. [DOI:10.1007/s40620-017-0392-z] [PMID]

Rybak LP, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Seminars in Hearing. 2019; 40(2):197-204. [DOI:10.1055/s-0039-1684048] [PMID]

Shahid F, Farooqui Z, Khan F. Cisplatin-induced gastrointestinal toxicity: An update on possible mechanisms and on available gastroprotective strategies. European Journal of Pharmacology. 2018; 827:49-57. [DOI:10.1016/j.ejphar.2018.03.009] [PMID]

Santos NAGD, Ferreira RS, Santos ACD. Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents. Food and Chemical Toxicology : An International Journal Published for the British Industrial Biological Research Association. 2020; 136:111079. [DOI:10.1016/j.fct.2019.111079] [PMID]

Chen SH, Chang JY. New insights into mechanisms of cisplatin resistance: From tumor cell to microenvironment. International Journal of Molecular Sciences. 2019; 20(17):4136. [DOI:10.3390/ijms20174136] [PMID]

Pan Z, Zhang H, Dokudovskaya S. The role of mTORC1 pathway and autophagy in resistance to platinum-based chemotherapeutics. International Journal of Molecular Sciences. 2023; 24(13):10651. [DOI:10.3390/ijms241310651] [PMID]

Yang XL, Zhang LL, Kou J, Zhou GQ, Wu CF, Sun Y, et al. Cisplatin-based concurrent chemoradiotherapy improved the survival of locoregionally advanced nasopharyngeal carcinoma after induction chemotherapy by reducing early treatment failure. BMC Cancer. 2022; 22(1):1230. [DOI:10.1186/s12885-022-10237-8] [PMID]

Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011; 3(1):1351-71. [DOI:10.3390/cancers3011351] [PMID]

Achkar IW, Abdulrahman N, Al-Sulaiti H, Joseph JM, Uddin S, Mraiche F. Cisplatin based therapy: The role of the mitogen activated protein kinase signaling pathway. Journal of Translational Medicine. 2018; 16:96. [DOI:10.1186/s12967-018-1471-1] [PMID]

Petrović M, Todorović D. Biochemical and molecular mechanisms of action of cisplatin in cancer cells. Facta Universitatis, Series: Medicine and Biology. 2016; 18(1):12-8. [Link]

Alderden RA, Hall MD, Hambley TW. The discovery and development of cisplatin. Journal of Chemical Education. 2006; 83(5):728. [DOI:10.1021/ed083p728]

Bugarčić ŽD, Bogojeski J, Petrović B, Hochreuther S, van Eldik R. Mechanistic studies on the reactions of platinum (II) complexes with nitrogen-and sulfur-donor biomolecules. Dalton transactions (Cambridge, England: 2003). 2012; 41(40):12329-45. [DOI:10.1039/c2dt31045g] [PMID]

Yu Y, Zhang L, Qin Z, Karges J, Xiao H, Su X. Unraveling and overcoming platinum drug- resistant cancer tumors with DNA Nanostructures. Advanced Functional Materials. 2023; 33(2):2208797. [DOI:10.1002/adfm.202208797]

Bejček J, Spiwok V, Kmoníčková E, Rimpelová S. Na+/K+-ATPase revisited: On its mechanism of action, role in cancer, and activity modulation. Molecules (Basel, Switzerland). 2021; 26(7):1905. [DOI:10.3390/molecules26071905] [PMID]

Fuertes MA, Castilla J, Alonso C, Pérez JM. Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Current Medicinal Chemistry. 2003; 10(34):257-66. [DOI:10.2174/0929867033368484] [PMID]

Martinho N, Santos TCB, Florindo HF, Silva LC. Cisplatin-membrane interactions and their influence on platinum complexes activity and toxicity. Frontiers in Physiology. 2019; 9:1898. [DOI:10.3389/fphys.2018.01898] [PMID]

Melnikov SV, Söll D, Steitz TA, Polikanov YS. Insights into RNA binding by the anticancer drug cisplatin from the crystal structure of cisplatin-modified ribosome. Nucleic Acids Research. 2016; 44(10):4978-87. [DOI:10.1093/nar/gkw246] [PMID]

Kozubík A, Vaculová A, Soucek K, Vondrácek J, Turánek J, Hofmanová J. Novel anticancer platinum(IV) complexes with adamantylamine: Their efficiency and innovative chemotherapy strategies modifying lipid metabolism. Metal-Based Drugs. 2008; 2008:417897. [DOI:10.1155/2008/417897] [PMID]

Corinti D, Paciotti R, Re N, Coletti C, Chiavarino B, Crestoni ME, et al. Binding motifs of cisplatin interaction with simple biomolecules and aminoacid targets probed by IR ion spectroscopy. Pure and Applied Chemistry. 2020; 92(1):3-13. [DOI:10.1515/pac-2019-0110]

Balendiran GK, Dabur R, Fraser D. The role of glutathione in cancer. Cell Biochemistry and Function. 2004; 22(6):343-52. [DOI:10.1002/cbf.1149] [PMID]

Jansen BA, Brouwer J, Reedijk J. Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs. Urnal of Inorganic Biochemistry. 2002; 89(3-4):197-202. [DOI:10.1016/S0162-0134(02)00381-1] [PMID]

Ishida R, Takaoka Y, Yamamoto S, Miyazaki T, Otaka M, Watanabe S, et al. Cisplatin differently affects amino terminal and carboxyl terminal domains of HSP90. FEBS Letters. 2008; 582(28):3879-83. [DOI:10.1016/j.febslet.2008.10.029] [PMID]

Brown MA, Zhu L, Schmidt C, Tucker PW. Hsp90--from signal transduction to cell transformation. Biochemical and Biophysical Research Communications. 2007; 363(2):241-6. [DOI:10.1016/j.bbrc.2007.08.054] [PMID]

Ahmad S. Kinetic aspects of platinum anticancer agents. Polyhedron. 2017; 138:109-24. [DOI:10.1016/j.poly.2017.09.016]

Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treatment Reviews. 2007; 33(1):9-23. [DOI:10.1016/j.ctrv.2006.09.006] [PMID]

Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature Reviews. Cancer. 2007; 7(8):573-84. [DOI:10.1038/nrc2167] [PMID]

Imamura T, Izumi H, Nagatani G, Ise T, Nomoto M, Iwamoto Y, Kohno K. Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein. The Journal of Biological Chemistry. 2001; 276(10):7534-40. [DOI:10.1074/jbc.M008143200] [PMID]

Zamble DB, Mikata Y, Eng CH, Sandman KE, Lippard SJ. Testis-specific HMG-domain protein alters the responses of cells to cisplatin. Journal of Inorganic Biochemistry. 2002; 91(3):451-62. [DOI:10.1016/S0162-0134(02)00472-5] [PMID]

Spivak G. Nucleotide excision repair in humans. DNA Repair (Amst). 2015; 36:13-8. [DOI:10.1016/j.dnarep.2015.09.003] [PMID]

Enoiu M, Jiricny J, Schärer OD. Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis. Nucleic Acids Research. 2012; 40(18):8953-64. [DOI:10.1093/nar/gks670] [PMID]

Gandin V, Hoeschele JD, Margiotta N. Special issue “Cisplatin in cancer therapy: Molecular Mechanisms of Action 3.0”. International Journal of Molecular Sciences. 2023; 24(9):7917. [PMID]

Ranasinghe R, Mathai ML, Zulli A. Cisplatin for cancer therapy and overcoming chemoresistance. Heliyon. 2022; 8(9):e10608. [DOI:10.1016/j.heliyon.2022.e10608] [PMID]

Rocha CRR, Silva MM, Quinet A, Cabral-Neto JB, Menck CFM. DNA repair pathways and cisplatin resistance: An intimate relationship. Clinics. 2018; 73:e478s. [DOI:10.6061/clinics/2018/e478s] [PMID]

Brabec V, Kasparkova J. Modifications of DNA by platinum complexes: Relation to resistance of tumors to platinum antitumor drugs. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 2005; 8(3):131-46. [DOI:10.1016/j.drup.2005.04.006] [PMID]

Sedletska Y, Giraud-Panis MJ, Malinge JM. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: Importance of apoptotic pathways. Current Medicinal Chemistry. 2005; 5(3):251-65. [DOI:10.2174/1568011053765967] [PMID]

Dewhirst MW, Secomb TW. Transport of drugs from blood vessels to tumour tissue. Nature Reviews. Cancer. 2017; 17(12):738-50. [DOI:10.1038/nrc.2017.93] [PMID]

Strese S, Fryknäs M, Larsson R, Gullbo J. Effects of hypoxia on human cancer cell line chemosensitivity. BMC Cancer. 2013; 13:331. [DOI:10.1186/1471-2407-13-331] [PMID]

Stewart DJ, Benjamin RS, Luna M, Feun L, Caprioli R, Seifert W, et al. Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol. 1982; 10:51-4. [DOI:10.1007/BF00257239] [PMID]

Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Critical Reviews in Oncology/Hematology. 2007; 63(1):12-31. [DOI:10.1016/j.critrevonc.2007.02.001] [PMID]

Miao L, Wang Y, Lin CM, Xiong Y, Chen N, Zhang L, et al. Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. Journal of Controlled Release: Official Journal of the Controlled Release Society. 2015; 217:27-41. [DOI:10.1016/j.jconrel.2015.08.027] [PMID]

Xu M, Zhang T, Xia R, Wei Y, Wei X. Targeting the tumor stroma for cancer therapy. Molecular Cancer. 2022; 21(1):208. [DOI:10.1186/s12943-022-01670-1] [PMID]

Berardi R, Torniai M, Lenci E, Pecci F, Morgese F, Rinaldi S. Electrolyte disorders in cancer patients: A systematic review. Journal of Cancer Metastasis and Treatment. 2019; 5:79. [DOI:10.20517/2394-4722.2019.008]

Wang K, Lu J, Li R. The events that occur when cisplatin encounters cells. Coordination Chemistry Reviews. 1996; 151:53-88. [DOI:10.1016/S0010-8545(96)90195-2]

Nakagawa T, Inoue Y, Kodama H, Yamazaki H, Kawai K, Suemizu H, et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts. Oncology Reports. 2008; 2:265-70. [DOI:10.3892/or_00000002]

Zhang C, Gao S, Hou J. ERCC1 expression and platinum chemosensitivity in patients with ovarian cancer: A meta-analysis. The International Journal of Biological Markers. 2020; 35(4):12-9. [DOI:10.1177/1724600820963396] [PMID]

Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nature Medicine. 2003; 9(5):568-74. [DOI:10.1038/nm852] [PMID]

Martin SK, Wood RD. DNA polymerase ζ in DNA replication and repair. Nucleic Acids Research. 2019; 47(16):8348-61. [DOI:10.1093/nar/gkz705] [PMID]

de Campos-Nebel M, Larripa I, González-Cid M. Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination. PLoS One. 2010; 5(9):e12541. [DOI:10.1371/journal.pone.0012541] [PMID]

Sawant A, Kothandapani A, Zhitkovich A, Sobol RW, Patrick SM. Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links. DNA Repair. 2015; 35:126-36. [DOI:10.1016/j.dnarep.2015.10.003] [PMID]

Song K, Artibani M. The role of DNA methylation in ovarian cancer chemoresistance: A narrative review. Health Science Reports. 2023; 6(5):e1235. [DOI:10.1002/hsr2.1235] [PMID]

Zhao H, Eguchi S, Alam A, Ma D. The role of nuclear factor-erythroid 2 related factor 2 (Nrf-2) in the protection against lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology. 2017; 312(2):L155-62. [DOI:10.1152/ajplung.00449.2016] [PMID]

Arabnezhad MR, Haghani F, Ghaffarian-Bahraman A, Jafarzadeh E, Mohammadi H, Yadegari JG, et al. Involvement of Nrf2 signaling in lead-induced toxicity. Current Medicinal Chemistry. 2023. [DOI:10.2174/0929867330666230522143341] [PMID]

Wang R, Liang L, Matsumoto M, Iwata K, Umemura A, He F. Reactive Oxygen Species and NRF2 Signaling, Friends or Foes in Cancer? Biomolecules. 2023; 13(2):353. [DOI:10.3390/biom13020353] [PMID]

Mirzaei S, Mohammadi AT, Gholami MH, Hashemi F, Zarrabi A, Zabolian A, et al. Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance. Pharmacological Research. 2021; 167:105575. [DOI:10.1016/j.phrs.2021.105575] [PMID]

Wang P, Long F, Lin H, Wang S, Wang T. Dietary phytochemicals targeting Nrf2 to enhance the radiosensitivity of cancer. Oxidative Medicine and Cellular Longevity. 2022; 2022:7848811. [DOI:10.1155/2022/7848811] [PMID]

Kim EH, Ridlo MR, Lee BC, Kim GA. Melatonin-Nrf2 signaling activates peroxisomal activities in porcine cumulus cell-oocyte complexes. Antioxidants (Basel, Switzerland). 2020; 9(11):1080. [DOI:10.3390/antiox9111080] [PMID]

Klaassen CD, Watkins JB. Casarett & Doull’s essentials of toxicology. New York: McGraw-Hill Education; 2021. [Link]

Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. BioMed Research International. 2014; 2014:967826. [DOI:10.1155/2014/967826] [PMID]

Sheth S, Mukherjea D, Rybak LP, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and otoprotection. Frontiers in Cellular Neuroscience. 2017; 11:338. [DOI:10.3389/fncel.2017.00338] [PMID]

Hoffman RS, Nelson LS, Goldfrank LR, Howland MA, Lewin NA, Smith SW. Goldfrank’s toxicologic emergencies. New York: McGraw-Hill Education; 2019. [Link]

Shin Y, Kim B, Kim W. Cisplatin-Induced Nausea and Vomiting: Effect of Herbal Medicines. Plants (Basel, Switzerland). 2022; 11(23):3395. [DOI:10.3390/plants11233395] [PMID]

Katzung BG, Trevor AJ. Basic and Clinical Pharmacology. New York: McGraw-Hill Education; 2021. [Link]

Minami M, Endo T, Hirafuji M, Hamaue N, Liu Y, Hiroshige T, et al. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacology & Therapeutics. 2003; 99(2):149-65. [DOI:10.1016/S0163-7258(03)00057-3] [PMID]

Tsang RY, Al-Fayea T, Au HJ. Cisplatin overdose: Toxicities and management. Drug Safety. 2009; 32:1109-22. [DOI:10.2165/11316640-000000000-00000] [PMID]

Lu Y, Cederbaum AI. Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicological Sciences: An Official Journal of the Society of Toxicology. 2006; 89(2):515-23. [DOI:10.1093/toxsci/kfj031] [PMID]

Mir M, Arab Mr, Shahraki Mr, Mashhadi Ma, Shahraki Sm, Sargolzaei Af, et al. Toxic effects of cisplatin on hepatocytes and liver enzymes of rats. Anatomical Sciences Journal. 2015; 12(4):171-6. [Link]

Caro AA, Cederbaum AI. Oxidative stress, toxicology, and pharmacology of CYP2E1. Annual Review of Pharmacology and Toxicology. 2004; 44:27-42. [DOI:10.1146/annurev.pharmtox.44.101802.121704] [PMID]

Liao Y, Lu X, Lu C, Li G, Jin Y, Tang H. Selection of agents for prevention of cisplatin-induced hepatotoxicity. Pharmacological Research. 2008; 57(2):125-31. [DOI:10.1016/j.phrs.2008.01.001] [PMID]

Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opinion on Pharmacotherapy. 2003; 4(6):889-901. [DOI:10.1517/14656566.4.6.889] [PMID]

Song B, Yang C, Wang L. Fatal overdosage with cisplatin by accidental substitution for carboplatin: A case report. International Journal of Clinical and Experimental Medicine. 2018; 11(5):5275-80. [Link]

Hayati F, Hossainzadeh M, Shayanpour S, Abedi-Gheshlaghi Z, Beladi Mousavi SS. Prevention of cisplatin nephrotoxicity. Journal of Nephropharmacology. 2015; 5(1):57-60. [PMID] [PMCID]

Jafarzadeh E, Shoeibi S, Bahramvand Y, Nasrollahi E, Maghsoudi AS, Yazdi F, et al. Turmeric for treatment of irritable bowel syndrome: A systematic review of population-based evidence. Iranian Journal of Public Health. 2022; 51(6):1223-31. [DOI:10.18502/ijph.v51i6.9656] [PMID]

Haddad LM, Shannon MW, Winchester JF. Clinical management of poisoning and drug overdose. Philadelphia: Saunders; 1998. [Link]

Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Seminars in Oncology. 1999; 26(2 Suppl 7):3-21. [PMID]

Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2009; 27(1):127-45. [DOI:10.1200/JCO.2008.17.2627] [PMID]

Ma X, Yu J, Yan R, Yan M, Xu Q. Promoting effect of crystal water leading to catalyst-free synthesis of heteroaryl thioether from heteroaryl chloride, sodium thiosulfate pentahydrate, and alcohol. The Journal of Organic Chemistry. 2019; 84(17):11294-300. [DOI:10.1021/acs.joc.9b01670] [PMID]

Hazlitt RA, Min J, Zuo J. Progress in the development of preventative drugs for cisplatin-induced hearing loss: Miniperspective. Journal of Medicinal Chemistry. 2018; 61(13):5512-24. [DOI:10.1021/acs.jmedchem.7b01653] [PMID]

Wu YJ, Muldoon LL, Neuwelt EA. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. The Journal of Pharmacology and Experimental Therapeutics. 2005; 312(2):424-31. [DOI:10.1124/jpet.104.075119] [PMID]

Benoehr P, Krueth P, Bokemeyer C, Grenz A, Osswald H, Hartmann JT. Nephroprotection by theophylline in patients with cisplatin chemotherapy: A randomized, single-blinded, placebo-controlled trial. Journal of the American Society of Nephrology: JASN. 2005; 16(2):452-8. [DOI:10.1681/ASN.2004030225] [PMID]

Heyman SN, Spokes K, Egorin MJ, Epstein FH. Glycine reduces early renal parenchymal uptake of cisplatin. Kidney International. 1993; 43(6):1226-8. [DOI:10.1038/ki.1993.173] [PMID]

Salehi Z, Roayaei M. Effect of Vitamin E on oxaliplatin-induced peripheral neuropathy prevention: A randomized controlled trial. International Journal of Preventive Medicine. 2015; 6:104. [DOI:10.4103/2008-7802.169021] [PMID]

Zhanel GG, Walkty AJ, Karlowsky JA. Fosfomycin: A first-line oral therapy for acute uncomplicated cystitis. The Canadian Journal of Infectious Diseases & Medical Microbiology= Journal canadien des maladies infectieuses et de la microbiologie medicale. 2016; 2016:2082693. [DOI:10.1155/2016/2082693] [PMID]

Church MW, Kaltenbach JA, Blakley BW, Burgio DL. The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hearing Research. 1995; 86(1-2):195-203. [DOI:10.1016/0378-5955(95)00066-D] [PMID]

Jalali A, Zafari J, Jouni FJ, Abdolmaleki P, Shirazi FH, Khodayar MJ. Combination of static magnetic field and cisplatin in order to reduce drug resistance in cancer cell lines. International Journal of Radiation Biology. 2019; 95(8):1194-201. [DOI:10.1080/09553002.2019.1589012] [PMID]

Rastegar-Pouyani N, Montazeri V, Marandi N, Aliebrahimi S, Andalib M, Jafarzadeh E, et al. The impact of Cancer-Associated Fibroblasts on drug resistance, stemness, and epithelial-mesenchymal transition in Bladder Cancer: A comparison between recurrent and non-recurrent patient-derived CAFs. Cancer Investigation. 2023; 41(7):656–71. [DOI:10.1080/07357907.2023.2237576] [PMID]

Moslehi M, Rezaei S, Talebzadeh P, Ansari MJ, Jawad MA, Jalil AT, et al. Apigenin in cancer therapy: Prevention of genomic instability and anticancer mechanisms. Clinical and Experimental Pharmacology & Physiology. 2022; 50(1):3-18. [DOI:10.1111/1440-1681.13725] [PMID]

Amini P, Moazamiyanfar R, Dakkali MS, Khani A, Jafarzadeh E, Mouludi K, et al. Resveratrol in cancer therapy: From stimulation of genomic stability to adjuvant cancer therapy: A comprehensive review. Current Topics in Medicinal Chemistry. 2023; 23(8):629-48. [DOI:10.2174/1568026623666221014152759] [PMID]

Moazamiyanfar R, Rezaei S, Ashrafzadeh HA, Rastegar-Pouyani N, Jafarzadeh E, Mouludi K, et al. Nobiletin in cancer therapy; mechanisms and therapy perspectives. Current Pharmaceutical Design. 2023; 29(22):1713-28. [DOI:10.2174/1381612829666230426115424] [PMID]

Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017; 8(23):38022-43. [DOI:10.18632/oncotarget.16723] [PMID]

Ni JJ, Zhang ZZ, Ge MJ, Chen JY, Zhuo W. Immune-based combination therapy to convert immunologically cold tumors into hot tumors: An update and new insights. Acta Pharmacologica Sinica. 2023; 44(2):288-307. [PMID]

Kamalipooya S, Abdolmaleki P, Salemi Z, Javani Jouni F, Zafari J, Soleimani H. Simultaneous application of cisplatin and static magnetic field enhances oxidative stress in HeLa cell line. In Vitro Cellular & Developmental Biology. Animal. 2017; 53(9):783-90. [DOI:10.1007/s11626-017-0148-z] [PMID]

Zafari J, Zadehmodarres S, Jouni FJ, Bagheri-Hosseinabadi Z, Najjar N, Asnaashari M. Investigation into the effect of photodynamic therapy and cisplatin on the cervical cancer cell line (A2780). Journal of Lasers in Medical Sciences. 2020; 11(Suppl 1):S85-91. [DOI:10.34172/jlms.2020.S14] [PMID]

Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1992; 10(2):257-63. [DOI:10.1200/JCO.1992.10.2.257] [PMID]

Pinto A, Pocard M. Hyperthermic intraperitoneal chemotherapy with cisplatin and mitomycin C for colorectal cancer peritoneal metastases: A systematic review of the literature. Pleura and Peritoneum. 2019;4(2):20190006. [DOI:10.1515/pp-2019-0006] [PMID]

Hussain MHA, Glass TR, Forman J, Sakr W, Smith DC, Al-Sarraf M, et al. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: A Southwest Oncology Group Study. The Journal of Urology. 2001; 165(1):56-61. [DOI:10.1097/00005392-200101000-00014] [PMID]

Friedlander M, Kaye SB, Sullivan A, Atkinson K, Elliott P, Coppleson M, et al. Cervical carcinoma: A drug-responsive tumor-experience with combined cisplatin, vinblastine, and bleomycin therapy. Gynecologic Oncology. 1983; 16(2):275-81. [DOI:10.1016/0090-8258(83)90102-6] [PMID]

Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo. Journal of Experimental & Clinical Cancer Research: CR. 2010; 29(1):87. [DOI:10.1186/1756-9966-29-87] [PMID]

McPherson RA, Galettis PT, De Souza PL. Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. British Journal of Cancer. 2009; 100(4):649-55. [DOI:10.1038/sj.bjc.6604920] [PMID]

Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity. Seminars in Oncology. 1999; 26(4 Suppl 12):89-95. [DOI:10.1038/sj.bjc.6604920] [PMID]

McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. The New England Journal of Medicine. 1996; 334(1):1-6. [DOI:10.1056/NEJM199601043340101] [PMID]

Cai L, Xu G, Shi C, Guo D, Wang X, Luo J. Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment. Biomaterials. 2015; 37:456-68. [DOI:10.1016/j.biomaterials.2014.10.044] [PMID]

Peng DJ, Wang J, Zhou JY, Wu GS. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochemical and Biophysical Research Communications. 2010; 394(3):600-5. [DOI:10.1016/j.bbrc.2010.03.029] [PMID]